University of Miami

Berg LLC

Other

Berg Pharma LLC

Indushekhar Persaud

Niven Rajin Narain

Sung Lan Hsia

Karrune Veeraprasert Woan

Jie Li

Kathryn J Russell

John Patrick McCook

Sung L Hsia

John Patrick Mccook

Patrick Mccook John

Kathryn J Rusell

Niven R Narain

The present disclosure relates to a method of inducing apoptosis in a cancer cell by delivery of exogenous Coenzyme Q1O or its metabolites thereof in a pharmaceutically acceptable carrier to effectuate cell contact of endogenous Coenzyme Q1O or its metabolites thereof in addition to but not limited to mevalonic acid and oleic acid to form an intracellular complex. The present disclosure also provides a method of modulating the p53 pathway and Bcl-2 protein family in a manner that restores the apoptotic potential to a cancer cell by delivery of Coenzyme Q1O in a pharmaceutically acceptable carrier. The present disclosure further provides a method to specifically normalize the ratio of pro-apoptotic and anti-apoptotic members of the Bcl-2 gene family in a proportion to re-program a cancer cell to undergo apoptosis.

Methods and use of inducing apoptosis in cancer cells

The present disclosure provides compositions suitable for delivering lipophilic bioactive agents. The compositions may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent.

Topical formulations having enhanced bioavailability

CoQlO has a stimulatory effect on fibroblasts and keratinocytes, increases ATP production, decreases pain. The formulations are useful for promoting acute wound healing, fatigue and treatment of acute and chronic pain.

Topical co-enzyme Q10 formulations and treatment of pain, fatigue and wounds

Systems and kits are provided which are capable of determining the oncogenicity of a cancer, tumor progression, and effectiveness of a cancer treatment. Such systems and kits utilize assays to examine the levels of apoptotic markers, angiogenesis markers, immunomodulation markers, and cell cycle markers and can compare samples from a patient taken at different times to determine the oncogenicity of a cancer, tumor progression, and effectiveness of a cancer treatment. Methods for determining the oncogenicity of a cancer, tumor progression, and effectiveness of a cancer treatment with such systems and kits are also provided.

Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy

Topical formulations of CoQ10 reduce the rate of tumor growth in an animcal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.

Topical co-enzyme Q10 formulations and methods of use

Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.

Growing community of inventors

Homestead, FL, United States of America

Indushekhar Persaud